Investigational drug · Phase 3
TSND-201
Also called: methylone
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Post Traumatic Stress Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
3 still active
All registered trials
5
Any phase or sponsor naming "TSND-201"
First trial start
2023
Mar 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TSND-201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Post Traumatic Stress Disorder
Largest trials
Live from ClinicalTrials.gov: studies naming "TSND-201" as an intervention, largest first.
- An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)Pivotal-lookingRecruiting
Transcend TherapeuticsIndustry
NCT07456696 · 300 participants (planned) · Start Apr 2, 2026 · Primary completion Dec 2027
Drug: TSND-201; Placebo · For: Post Traumatic Stress Disorder
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 37 sites in all
- An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSDPivotal-lookingEnrolling by invitation
Transcend TherapeuticsIndustry
NCT07670702 · 300 participants (planned) · Start Jun 22, 2026 · Primary completion Dec 2028
Drug: TSND-201 · For: Post Traumatic Stress Disorder
Sites: Little Rock, Arkansas; Los Angeles, California; Montclair, California · 17 sites in all
- An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSDPivotal-lookingRecruiting
Transcend TherapeuticsIndustry
NCT07836647 · 300 participants (planned) · Start Sep 25, 2026 · Primary completion Feb 2028
Drug: TSND-201; Placebo · For: Post Traumatic Stress Disorder
Sites: Denver, Colorado; Bradenton, Florida; Orlando, Florida · 9 sites in all
Transcend TherapeuticsIndustry
NCT06215261 · 62 participants · Start Apr 4, 2024 · Primary completion Sep 23, 2025
Drug: Methylone · For: Post Traumatic Stress Disorder
Sites: Lauderhill, Florida; Maitland, Florida; Orlando, Florida · 12 sites in all
Transcend TherapeuticsIndustry
NCT06237426 · 44 participants · Start Mar 6, 2024 · Primary completion Oct 6, 2025
Drug: Methylone · For: Post Traumatic Stress Disorder
Sites: Denver, Colorado; Rockville, Maryland; Draper, Utah · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Alkyl-Chain Extension and Terminal Amine Substitution Shape Cardiotoxic Profiles of Methylenedioxy Cathinones in Zebrafish Embryos.
Aljabasini O, Tagkalidou N, Pazos MD, et al. · Pharmaceuticals (Basel) 2026
- Impact of nano zero valent iron dosing on biotransformation and adsorption of 20 biomarkers in sewers.
Ren J, Cen X, Li J, et al. · Water Res 2026
- Enantioselective determination of methylone and its major phase 1 metabolites in various biological matrices and stereochemical stability of methylone enantiomers.
Sprega G, Kobidze G, Montana A, et al. · Drug Metab Dispos 2026
- Emergency Department presentations due to new psychoactive substances (NPS) and other illicit drugs: a clinical and toxicological study on recreational drug toxicity in Italy.
Giorgetti A, Venturi A, Barone R, et al. · Int J Legal Med 2026
- Locomotor and discriminative stimulus effects of N-cyclohexyl butylone and N-cyclohexyl methylone.
Gatch MB, Jia S, Shetty RA, et al. · Front Pharmacol 2026
- Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial.
Jones A, Warner-Schmidt J, Kwak H, et al. · JAMA Psychiatry 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.